North America Uterine Cancer Therapeutics and Diagnostics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The north america uterine cancer therapeutics and diagnostics market size was valued at USD 9.97 billion in 2025 and is estimated to grow from USD 10.39 billion in 2026 to reach USD 12.75 billion by 2031, at a CAGR of 4.18% during the forecast period (2026-2031). This report is Segmented by Cancer Type (Endometrial Cancer, Uterine Sarcoma), Procedure (Treatment [Surgery and More], Diagnostics [Biopsy and More]), End User (Hospitals, Diagnostic Laboratories, Specialty Cancer Centers, Ambulatory Surgical Centers, and More), and Country (United States, Canada, and Mexico). Market Forecasts is Given in Values (USD).

North America Uterine Cancer Therapeutics and Diagnostics Market Trends and Insights

Increasing Healthcare Expenditure Expanding Oncology Budgets

The North American uterine cancer therapeutics and diagnostics market benefits from rising oncology spending because newer uterine cancer therapies and high-value procedures cost much more per patient than older standards of care. This effect is most visible in advanced endometrial cancer, where immunotherapy-based regimens have raised treatment intensity and budget exposure across hospitals and public drug plans.Hospitals are also investing more in robotic surgery capacity, and that supports procedure revenue, service contracts, and associated diagnostic workups across the North American uterine cancer therapeutics and diagnostics market.

Innovation in Drug Development and Technological Advancements

The North American uterine cancer therapeutics and diagnostics market saw a major treatment shift in 2024 when the FDA approved pembrolizumab, durvalumab, and dostarlimab for advanced or recurrent endometrial cancer. These approvals established checkpoint inhibitor use much earlier in the patient pathway and made biomarker testing more central to clinical decision-making. The August 2024 dostarlimab expansion was especially important because it widened first-line eligibility to adult patients regardless of MMR status and covered the much larger MMRp and MSS population.

Diagnostic innovation is moving in parallel, with 2025 literature highlighting liquid biopsy, ctDNA analysis, and AI supported interpretation as tools that may improve earlier and less invasive detection.

Rising Awareness About Uterine Diseases and Available Therapies

Awareness of postmenopausal bleeding remains important because it supports earlier presentation and keeps diagnostic throughput high across the North American uterine cancer therapeutics and diagnostics market. National surveillance data show that a large share of uterine corpus cancer cases are still detected at the localized stage, which supports better treatment timing and creates steady demand for biopsy, imaging, pathology, and follow-up services.

In Mexico, the 2025 Segundo Consenso Mexicano de Cáncer de Endometrio identified low public awareness of early symptoms as a key reason for later stage presentation outside large urban centers. As awareness improves, the North American uterine cancer therapeutics and diagnostics market should continue to see more complete patient journeys from symptom recognition to specialist workup and treatment initiation.

Other drivers and restraints analyzed in the detailed report include:

• Underdiagnosis in High-Risk Populations Creates Unmet Demand for Screening and Diagnostic Reach
• Low Success Rate in Clinical Trials and High Cost of Research and Development
• High Treatment Cost Creating Access Barriers Across the Region

Segment Analysis

Endometrial cancer accounted for 88.23% of the North America uterine cancer therapeutics and diagnostics market size in 2025, reflecting its overwhelming weight in regional case volumes and routine care demand. The segment’s scale is supported by the American Cancer Society estimate of 68,270 new uterine corpus cancer cases in the United States in 2026 and by Health Canada approval materials that referenced close to 8,600 annual uterine cancer diagnoses in Canada. Rising obesity and diabetes prevalence should keep demand firm because both conditions remain established risk factors and continue to enlarge the exposed patient base over time.

Uterine sarcoma is projected to expand at an 8.82% CAGR through 2031, making it the faster-moving cancer type even though its absolute patient base remains much smaller than that of endometrial cancer. Growth in this segment is being driven by deeper molecular characterization, because current research has identified clinically relevant gene fusions and biological pathways that may support more tailored treatment development over time. A 2026 review in the International Journal of Gynecological Cancer described the management of advanced uterine sarcoma as an area with evolving systemic options and with ongoing interest in antibody-drug conjugates, which supports the view that therapeutic intensity is rising from a very limited base.

Complete Report Scope:

• By Cancer Type
  • Endometrial Cancer
  • Uterine Sarcoma
• By Procedure
  • Treatment
    • Surgery
    • Immunotherapy
    • Radiation Therapy
    • Chemotherapy
    • Other Treatments
  • Diagnostics
    • Biopsy
    • Ultrasound
    • Hysteroscopy
    • Dilation and Curettage
    • Other Diagnostics
• By End User
  • Hospitals
  • Diagnostic Laboratories
  • Specialty Cancer Centers
  • Ambulatory Surgical Centers
  • Other End Users
• By Country
  • United States
  • Canada
  • Mexico

List of Companies Covered in this Report:

• Abbvie
• AstraZeneca
• Bristol Myers Squibb (BMS)
• Eli Lilly and Company
• Exact Sciences
• GlaxoSmithKline
• Guardant Health, Inc.
• Guardant Health, Inc.
• Illumina
• Johnson & Johnson
• Merck
• Myriad Genetics
• Novartis
• Pfizer
• Pfizer
• Quest Diagnostics
• Roche
• Thermo Fisher Scientific

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support